Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.

J Immunol Res · 2014 · PMC3987796 · PMID 24741582

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In high-grade lymphomas, a multivariate analysis of patients with diffuse large B cell lymphoma treated with R-CHOP in the RICOVER-60 trial identified a nonsignificant trend towards an unfavorable outcome for carriers of Fc γ RIIIA p.158 F/F [ 17 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.